Expand MESO Menu
MESO MENU

MESO Latest Press Releases

-- April 29, 2024 --

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024 Globe Newswire 9:05 PM

-- March 25, 2024 --

United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD) Globe Newswire 10:34 PM

-- March 13, 2024 --

Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer Globe Newswire 7:30 PM

-- March 10, 2024 --

United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD) Globe Newswire 7:54 PM

-- February 28, 2024 --

Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023 Globe Newswire 5:57 PM

-- February 26, 2024 --

Mesoblast Financial Results and Corporate Update Webcast Globe Newswire 7:00 AM

-- February 14, 2024 --

United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor (Rexlemestrocel-L) in Children With Congenital Heart Disease Globe Newswire 7:46 PM

-- January 30, 2024 --

Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023 Globe Newswire 9:13 PM

-- January 18, 2024 --

United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor (Rexlemestrocel-L) in Children With Congenital Heart Disease Globe Newswire 6:36 PM